Tags

Type your tag names separated by a space and hit enter

Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain.

Abstract

OBJECTIVE

This study assessed the psychometric properties of the MOS Sleep Scale in neuropathic pain (NeP).

METHODS

Psychometric properties were tested in patients with neuropathic pain enrolled in a prospective study exploring the effectiveness of gabapentin for 3 months. Participants also completed scales for pain intensity, anxiety, depression, disability, and health-related quality of life. Feasibility, reliability, validity and sensitivity to change were measured in this study.

RESULTS

Six-hundred-three patients [58.4+/-14.4 years (65.1% female), mean+/-SD] with pain for 1.2+/-3.3 years were included. The MOS Sleep Scale was acceptable (items with missing data <10% and floor and ceiling effects <50% per item and <15% per domain) and reliable (Cronbach's alpha between 0.64 and 0.87, and test-retest intraclass correlation coefficients between 0.79 and 0.91, p<0.001 for all cases). After adjusting for confounders, the MOS Sleep Scale was able to distinguish between sex, present pain intensity, level of disability and presence of anxiety or depression. Correlations with other scales were moderate; rho-coefficients between -0.21 and 0.57 (p<0.01, all cases). The scale was sensitive to change after treatment with gabapentin; after adjusting, responders (50% reduction in baseline pain) showed a decrease in sleep problems index of -25.6+/-14.3 points vs. -12.1+14.5 points in nonresponders (F=80.5, df=1/398, p<0.0001). Score reduction in summary index and subscales correlated significantly with pain intensity reduction (Pearson r-coefficients between 0.428 and 0.116, p<0.01, all cases).

CONCLUSIONS

The MOS Sleep Scale showed good psychometric properties and was sensitive to changes in patients with NeP of broad aetiology.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Health Outcomes Research Department, Medical Unit, Pfizer España, Madrid, Spain. javier.rejas@pfizer.com

    , ,

    Source

    MeSH

    Adult
    Aged
    Amines
    Analgesics
    Anxiety
    Cyclohexanecarboxylic Acids
    Depression
    Disability Evaluation
    Female
    Gabapentin
    Humans
    Male
    Middle Aged
    Neuropsychological Tests
    Pain Measurement
    Pain, Intractable
    Peripheral Nervous System Diseases
    Predictive Value of Tests
    Prospective Studies
    Psychometrics
    Sleep Wake Disorders
    gamma-Aminobutyric Acid

    Pub Type(s)

    Clinical Trial
    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    16765622

    Citation

    Rejas, Javier, et al. "Psychometric Properties of the MOS (Medical Outcomes Study) Sleep Scale in Patients With Neuropathic Pain." European Journal of Pain (London, England), vol. 11, no. 3, 2007, pp. 329-40.
    Rejas J, Ribera MV, Ruiz M, et al. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain. 2007;11(3):329-40.
    Rejas, J., Ribera, M. V., Ruiz, M., & Masrramón, X. (2007). Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. European Journal of Pain (London, England), 11(3), pp. 329-40.
    Rejas J, et al. Psychometric Properties of the MOS (Medical Outcomes Study) Sleep Scale in Patients With Neuropathic Pain. Eur J Pain. 2007;11(3):329-40. PubMed PMID: 16765622.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. AU - Rejas,Javier, AU - Ribera,María Victoria, AU - Ruiz,Manuel, AU - Masrramón,Xavier, Y1 - 2006/06/12/ PY - 2005/07/21/received PY - 2006/04/05/revised PY - 2006/05/01/accepted PY - 2006/6/13/pubmed PY - 2007/4/20/medline PY - 2006/6/13/entrez SP - 329 EP - 40 JF - European journal of pain (London, England) JO - Eur J Pain VL - 11 IS - 3 N2 - OBJECTIVE: This study assessed the psychometric properties of the MOS Sleep Scale in neuropathic pain (NeP). METHODS: Psychometric properties were tested in patients with neuropathic pain enrolled in a prospective study exploring the effectiveness of gabapentin for 3 months. Participants also completed scales for pain intensity, anxiety, depression, disability, and health-related quality of life. Feasibility, reliability, validity and sensitivity to change were measured in this study. RESULTS: Six-hundred-three patients [58.4+/-14.4 years (65.1% female), mean+/-SD] with pain for 1.2+/-3.3 years were included. The MOS Sleep Scale was acceptable (items with missing data <10% and floor and ceiling effects <50% per item and <15% per domain) and reliable (Cronbach's alpha between 0.64 and 0.87, and test-retest intraclass correlation coefficients between 0.79 and 0.91, p<0.001 for all cases). After adjusting for confounders, the MOS Sleep Scale was able to distinguish between sex, present pain intensity, level of disability and presence of anxiety or depression. Correlations with other scales were moderate; rho-coefficients between -0.21 and 0.57 (p<0.01, all cases). The scale was sensitive to change after treatment with gabapentin; after adjusting, responders (50% reduction in baseline pain) showed a decrease in sleep problems index of -25.6+/-14.3 points vs. -12.1+14.5 points in nonresponders (F=80.5, df=1/398, p<0.0001). Score reduction in summary index and subscales correlated significantly with pain intensity reduction (Pearson r-coefficients between 0.428 and 0.116, p<0.01, all cases). CONCLUSIONS: The MOS Sleep Scale showed good psychometric properties and was sensitive to changes in patients with NeP of broad aetiology. SN - 1090-3801 UR - https://www.unboundmedicine.com/medline/citation/16765622/Psychometric_properties_of_the_MOS__Medical_Outcomes_Study__Sleep_Scale_in_patients_with_neuropathic_pain_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1090-3801(06)00068-1 DB - PRIME DP - Unbound Medicine ER -